Item 2.01. Completion of Acquisition or Disposition of Assets

On October 21, 2008, ViroPharma Incorporated ("ViroPharma") announced that it had completed the previously announced acquisition of Lev Pharmaceuticals, Inc. ("Lev"). Pursuant to the terms and conditions of the Agreement and Plan of Merger, dated July 15, 2008 (the "Agreement"), among ViroPharma, Lev, and HAE Acquisition Corp. ("Merger Sub"), on October 21, 2008 (the "Closing Date"), Merger Sub merged with and into Lev, with Lev surviving the merger as a subsidiary of ViroPharma.

ViroPharma filed a Form 8-K on October 24, 2008 (the "Initial Form 8-K") to report the completion of the acquisition. The purpose of this Form 8-K/A is to file the pro forma financial information required by Item 9.01 of Form 8-K, which was omitted from the Initial Form 8-K pursuant to paragraph (b)(2) of Item 9.01 of Form 8-K. The pro forma financial information is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of business acquired.

Previously filed.

(b) Pro forma financial information

The pro forma financial information required pursuant to Article 11 of Regulation S-X is filed herewith as, and incorporated herein by reference to, Exhibit 99.1 hereto.

(d) Exhibit No. Description
99.1 Unaudited Pro Forma Condensed Consolidated Financial Information.